SAN FRANCISCO — With a new deal to use CRISPR to hunt for new drugs, the drug maker GlaxoSmithKline and the leading academic gene-editing researchers it’s collaborating with are embarking on a first-of-its-kind partnership.
But the collaboration raises questions that are familiar to many partnerships between academic and industry researchers: What will each party get out of the deal? What will get published? And will GSK exert undue influence on what gets studied?
About the Author Reprints
